    Daniel Davis | Penumbra Inc | ZoomInfo.com

Daniel Donen Davis: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 8:38 AM ET
Healthcare Equipment and Supplies

Company Overview of Penumbra, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Daniel Donen Davis  Chief Commercial Officer & President of North America, Penumbra, Inc.AgeTotal Calculated CompensationThis person is connected to 0 Board Members in 0 different organizations across 1 different industries.39$2,444,701As of Fiscal Year 2016
Background

		Mr. Daniel Donen Davis has been Chief Commercial Officer and President of North America at Penumbra, Inc. since July 5, 2017 and 2015 respectively. Mr. Davis has thirteen years of experience in sales, marketing and business development with both early stage and Fortune 500 companies in medical devices and before that in software and consumer products. Prior to joining Penumbra, Mr. Davis served sales and marketing positions of increasing responsibility at Boston Scientific ... (now Stryker Neurovascular). He previously served as Vice President of Strategy from 2013 to 2014 and as Director of Marketing from 2011 to 2012. He joined Penumbra in 2007 in the pre-commercial phase to launch the first FDA cleared intracranial delivery catheter (Neuron), the first FDA cleared aspiration system for neurovascular mechanical thrombectomy (Penumbra System), and the Penumbra Coil 400 for the treatment of intracranial aneurysms. Mr. Davis received a B.A. from Duke University.Read Full Background




Corporate Headquarters
One Penumbra PlaceAlameda, California 94502United StatesPhone: 510-748-3200Fax: 510-748-3232
Board Members Memberships
				There is no Board Members Memberships data available.
				Education
BA Duke University
Other Affiliations
Duke University


Annual Compensation
Salary$500,000Total Annual Compensation$500,000
Stocks Options
Restricted Stock Awards$1,942,500All Other Compensation$2,201Exercisable Options$171,166Exercisable Options Value$9,365,219Unexercisable Options$95,834Unexercisable Options Value$4,929,701Total Value of Options$14,294,920Total Number of Options$267,000
Total Compensation
Total Annual Cash Compensation$502,201Total Short Term Compensation$500,000Other Long Term Compensation$1,944,701Total Calculated Compensation$2,444,701




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationScott William Drake Chief Executive Officer, President and DirectorThe Spectranetics Corporation$648.7KMichael H. Carrel Chief Executive Officer, President and DirectorAtriCure, Inc.$645.8KJames C. Clemmer Chief Executive Officer, President and DirectorAngioDynamics, Inc.$84.1KScott Raymond Ward MS, B.Sc.Chairman, Chief Executive Officer and PresidentCardiovascular Systems, Inc.$548.5KZhaohua  Chang Founder, Chairman and Chief Executive OfficerMicroPort Scientific Corporation$60.0KCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Penumbra, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft









Stock Screener - Yahoo FinanceHomeMailFlickrTumblrNewsSportsFinanceCelebrityAnswersGroupsMobileMoreYahooSearchSearch0U.S. Markets open in 52 mins.S&P Futures2,465.25-6.75 (-0.27%)Dow Futures21,712.00-31.00 (-0.14%)Insider TransactionsDefault CriteriaInsider & Restricted Shareholder Transactions1-25 of 32 resultsResults were generated a few mins ago. Pricing data is updated frequently. Currency in USDSymbolDateSharesProceedsTransaction DetailsPEN2017-02-092,200$157,000.00Automatic Sale at $70.70 - $72.40 per share.PEN2017-02-092,200$27,192.00Option Execute at $12.36 per share.PEN2017-02-082,800$34,608.00Option Execute at $12.36 per share.PEN2017-02-082,800$198,000.00Automatic Sale at $69.55 - $72.17 per share.PEN2017-02-073,624$44,793.00Option Execute at $12.36 per share.PEN2017-02-073,624$252,000.00Automatic Sale at $68.64 - $70.17 per share.PEN2017-02-061,300$90,000.00Automatic Sale at $68.90 - $69.58 per share.PEN2017-02-051,600$111,000.00Automatic Sale at $69.22 - $69.73 per share.PEN2017-02-022,708$190,000.00Automatic Sale at $69.83 - $70.64 per share.PEN2017-02-011,500$105,000.00Automatic Sale at $69.81 - $70.54 per share.PEN2017-01-311,600$114,000.00Automatic Sale at $70.78 - $71.60 per share.PEN2017-01-303,000$214,000.00Automatic Sale at $71.24 - $71.56 per share.PEN2017-01-292,698$191,000.00Automatic Sale at $70.48 - $71.04 per share.PEN2017-01-261,632$119,000.00Automatic Sale at $72.39 - $73.40 per share.PEN2017-01-253,315$245,000.00Automatic Sale at $72.93 - $75.00 per share.PEN2017-01-246,023$454,000.00Automatic Sale at $75.04 - $75.68 per share.PEN2017-01-024,809$306,814.00Disposition (Non Open Market) at $63.80 per share.PEN2016-11-1430,000N/AAcquisition (Non Open Market) at $0.00 per share.PEN2016-09-0510,700$760,000.00Automatic Sale at $70.87 - $71.22 per share.PEN2016-09-014,500$317,000.00Automatic Sale at $70.47 - $70.47 per share.PEN2016-08-312,400$168,000.00Automatic Sale at $69.90 - $70.39 per share.PEN2016-08-301,500$106,000.00Automatic Sale at $70.53 - $70.53 per share.PEN2016-08-291,800$128,000.00Automatic Sale at $71.13 - $71.13 per share.PEN2016-08-282,000$144,000.00Automatic Sale at $71.71 - $72.25 per share.PEN2016-08-253,600$257,000.00Automatic Sale at $70.99 - $71.65 per share.Show 25 rowsPrevNextTrump’s unwitting legacy could be universal health coverageYahoo FinanceSolar Eclipse 2017: Stay in the Tualatin ValleyThe Tualatin ValleySponsoredSean Hannity responds to claim he ran up a $42,000 tab at Trump's hotel after flying in a 70-year-old lobster from MaineBusiness InsiderYahoo Small BusinessData DisclaimerHelpSuggestionsPrivacyAbout Our AdsTerms (Updated)







Davis Daniel Donen, BizPedia.xyz - We monitor changes in companies





















BizPedia.xyz  - We monitor changes in companies
 






Davis Daniel Donen


FREE EMAIL WATCHDOG
Get free email notifications about news in Davis Daniel Donen.










The service is free and you can unsubscribe at any time.

General | Filings (14)
CIK Number: 0001651322


Earliest known filing
September 2015
Latest known filing
February 2017




Company filings
SEC filings are a great source of information for companies including investments, company events, and all sorts of other information. 
Davis Daniel Donen has 14 filings. View Davis Daniel Donen filings.
Similar companiesDAVISTON DOUGLAS T, Davisson William, Davisson Valerie, Davisson Timothy P., Davisson Robert J, DAVISSON PEDER KINLEY, DAVISSON JIM, DAVISONS DOWNTOWN LLC, Davison William H Jr, Davison William H, Davison Transportation Services, LLC, Davison Transportation Services, Inc., DAVISON THOMAS W, Davison Petroleum Supply, LLC, Davison Paul O, Davison Paul, DAVISON MICHAEL, Davison Lynn L, DAVISON LAMPON JOSE, Davison Joan M, DAVISON JEFFREY C, Davison James E Jr, Davison James E, Davison James Charles, DAVISON CHARLES, DAVISON C HAMILTON, Davison Brian C, Davison Barbara, Davison Arts Management, Inc., Davis-Stoudt Kelly, Davis-Standard LLC, Davis-Standard CORP, DAVIS-REA LTD., Davis-McHugh Marcy Kay, DAVIS-JOINT VENTURE BY TRANSCOASTL PARTNERS LLC-MANAGING VEN, Davis-Blake Alison, DAVIS WILLIE K, DAVIS WILLIE D, Davis William W., DAVIS WILLIAM W JR, DAVIS WILLIAM W, Davis William S, DAVIS WILLIAM L, DAVIS WILLIAM J, Davis William H, DAVIS WILLIAM GRENVILLE, DAVIS WILLIAM G JR, DAVIS WILLIAM G, DAVIS WILLIAM FRED JR, DAVIS WILLIAM FRED JR














BizPedia.xyz collect news, financial information, SEC filings, stock information, contact information, personal information, information about investments, etc. about Davis Daniel Donen. 















Davis Daniel Donen - Penumbra Inc Insider Transactions | TipRanks   





Go ProLogin / Sign Up Follow✓Get Real Time TransactionsInsider DetailsDavis Daniel DonenPenumbra Inc (PEN)President, North America Not RankedDavis Daniel Donen's PerformanceDavis Daniel Donen has not reported any informative transactions and therefore cannot be ranked.How are Insiders Ranked? Insider Holdings 100.0% Penumbra Inc (PEN)$7MSee the Top Stocks by Insiders > Insider RolesPenumbra Inc (PEN): President, North AmericaSee the Top 25 Corporate Insiders > Davis Daniel Donen's Trading Historybased on Form 4 Follow✓Get Real Time TransactionsCompany NameInsider PositionHolding ValueLast TransactionLast Transaction  AmountLast Transaction DatePENPenumbra IncPresident, North America$6,653,069Uninformative Sell$158,240.7Feb 14, 2017Davis Daniel Donen has not reported any informative transactions for PEN, therefore, performance cannot be measured. Track Record DateTransactionAmountNo. of SharesPrice per ShareProfitForm 4 Feb 14, 2017 Uninformative Sell $158K 2,200 $77 N/A  Feb 09, 2017 Uninformative Sell $543K 7,724 $72.1 N/A  Feb 06, 2017 Uninformative Sell $406K 5,808 $69.75 N/A Show MoreSee All Insider Trading from Today >You May Also LikeMeet our Smart Portfolio. See what top analysts say about your stocks.Get a breakdown of the different strategies based on detected insider trading activity.Find the best performing Analyst in each sector. Follow them so you never miss a recommendation.Related LinksHow can I benefit from Insider Trading? >See the Top 25 Corporate Insiders >Go to Hot Stocks by Insiders >Find which stocks Insiders traded today >Become a TipRanks MemberGet the best Investing Tips & Hacks straight to your emailFree MembershipSubmitInsider Trading Daily NewsletterProfessional day-trading strategy based on predictive insider transactionsAnnual Return: +85.42%Learn More >Powered by



























DAVIS DANIEL DONEN Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      DAVIS DANIEL DONEN
                    

•   ALAMEDA, CA
                      
How do I update this listing?




                                             Davis Daniel Donen is based out of Alameda.   
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from DAVIS DANIEL DONEN, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




davis daniel donen


1351 HARBOR BAY PARKWAY

ALAMEDA
CA
                                                        
                                                    94502









Recent SEC Filings




4 filed on 02/14/2017
4 filed on 02/09/2017
4 filed on 02/06/2017
4 filed on 02/01/2017
4 filed on 01/27/2017
4 filed on 01/05/2017
4 filed on 11/15/2016
4 filed on 09/06/2016
4 filed on 08/31/2016
4 filed on 08/29/2016
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free
















































Penumbra, Inc. (PEN) Upgraded at BidaskClub - American Banking News




















































Home
Get Email Updates
About
Disclaimer
Contact
Privacy Policy









 
			

















Business News
U.S. News
World News
Stock Ratings

Analysts' Upgrades
Analysts' Downgrades
Analysts' EPS Estimates
Analysts' Price Targets
Analysts' New Coverage


Corporate Earnings

Earnings Results
Earnings Guidance
Earnings Previews


Dividends
Insider Trades
Options
Press Releases






















Penumbra Inc. - Get News & Ratings Daily

		Enter your email address below to get the latest news and analysts' ratings for Penumbra Inc. with our FREE daily email newsletter:



 











 Recent Stories


Spirit Airlines, Inc. (NASDAQ:SAVE) Downgraded to Neutral at Buckingham Research


NiSource (NI) and National Grid Transco, PLC (NYSE:NGG) Critical Contrast


Valero Energy Partners LP (NYSE:VLP) Cut to Sell at Zacks Investment Research


8×8 Inc (EGHT) Stock Rating Lowered by Craig Hallum


Gentherm Inc (NASDAQ:THRM) Lowered to Hold at Craig Hallum


Texas Roadhouse, Inc. (TXRH) Earns “Buy” Rating from Maxim Group


Werner Enterprises, Inc. (NASDAQ:WERN) Upgraded at Zacks Investment Research


Astrazeneca PLC (NYSE:AZN) Stock Rating Lowered by Morgan Stanley


Loop Capital Boosts Mastercard Incorporated (MA) Price Target to $144.00


Alexion Pharmaceuticals, Inc. (ALXN) Given Overweight Rating at Morgan Stanley


Monness Crespi & Hardt Raises Imperva Inc (IMPV) Price Target to $57.00


Methanex Corporation (NASDAQ:MEOH) PT Lowered to $59.00 at Monness Crespi & Hardt


Rockwell Collins, Inc. (NYSE:COL) Earns “Buy” Rating from Cowen and Company


Controladora Vuela Compania de Aviacion, S.A.B. de C.V. (VLRS) Lowered to “Hold” at Zacks Investment Research


Interrent Real Estate Investment Trust (IIP.UN) Given Average Rating of “Buy” by Analysts


Boeing Company (The) (BA) Lifted to Neutral at Buckingham Research


Loop Capital Reaffirms “Buy” Rating for Cypress Semiconductor Corporation (NASDAQ:CY)


Just Group PLC (LON:JRP) Given Average Rating of “Buy” by Brokerages


Contrasting Iron Mountain (IRM) and Tangoe (TNGO)


Reviewing McGrath RentCorp (MGRC) & Neff Corporation (NEFF)





 






						Penumbra, Inc. (PEN) Upgraded at BidaskClub					

June 22nd, 2017  • 0 comments • Filed Under •
 by ABMN Staff



							Filed Under: Analysts Upgrades • Market News 






Tweet










Penumbra, Inc. (NYSE:PEN) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
Several other analysts have also recently issued reports on PEN. Canaccord Genuity  reaffirmed a “buy” rating and set a $91.00 price objective on shares of Penumbra in a report on Monday, March 27th. BMO Capital Markets  reaffirmed a “buy” rating and set a $86.00 price objective on shares of Penumbra in a report on Tuesday, April 11th. Finally, Zacks Investment Research cut Penumbra from a “hold” rating to a “sell” rating in a report on Thursday, May 11th.


 Get Penumbra Inc. alerts:



Shares of Penumbra (PEN) traded up 2.64% on Thursday, reaching $89.30. 198,070 shares of the company’s stock were exchanged. The firm has a market cap of $3.00 billion, a PE ratio of 320.07 and a beta of 0.15. Penumbra has a one year low of $54.96 and a one year high of $90.00. The company has a 50 day moving average price of $85.08 and a 200 day moving average price of $77.73. 




Penumbra (NYSE:PEN) last posted its quarterly earnings results on Tuesday, May 9th. The company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.04. The business had revenue of $73.21 million during the quarter, compared to analysts’ expectations of $71.08 million. Penumbra had a negative return on equity of 2.25% and a negative net margin of 2.31%. The firm’s revenue for the quarter was up 26.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.07 earnings per share.  Analysts expect that  Penumbra will post ($0.13) EPS for the current fiscal year. 
ILLEGAL ACTIVITY NOTICE: This article was originally  posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/06/22/penumbra-inc-pen-upgraded-at-bidaskclub.html. 
In other news, EVP Robert D. Evans sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, April 24th. The stock was sold at an average price of $85.24, for a total transaction of $852,400.00. Following the sale, the executive vice president now directly owns 12,075 shares of the company’s stock, valued at approximately $1,029,273. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 22.00% of the stock is owned by corporate insiders. 
Hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of  Penumbra during the fourth quarter valued at about $3,484,000.  State Board of Administration of Florida Retirement System boosted its stake in shares of  Penumbra by 0.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 13,245 shares of the company’s stock valued at $845,000 after buying an additional 120 shares during the period.  State Street Corp boosted its stake in shares of  Penumbra by 9.4% in the fourth quarter. State Street Corp now owns 472,199 shares of the company’s stock valued at $30,130,000 after buying an additional 40,596 shares during the period.  FMR LLC boosted its stake in shares of  Penumbra by 1.9% in the fourth quarter. FMR LLC now owns 4,746,579 shares of the company’s stock valued at $302,831,000 after buying an additional 88,389 shares during the period.  Finally, Marshall Wace LLP purchased a new stake in shares of  Penumbra during the fourth quarter valued at about $211,000. 68.67% of the stock is currently owned by institutional investors and hedge funds. 
About Penumbra
Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.




Receive News & Ratings for Penumbra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 































Leave a Reply

Click here to cancel reply.



Name (required)

Mail (will not be published) (required)

Website






Wordpress Hashcash needs javascript to work, but your browser has javascript disabled. Your comment will be placed in moderation!











			© Copyright American Banking and Market News 2006-2017. All rights reserved. 

Privacy Policy and Disclosures |
			About | Advertising 
			| Contact







Content on this website is not meant to be a recommendation or an offer to buy or sell any security. Click here to read our full disclaimer.









































